
Recently released data from Tzield’s PROTECT study showed that Tzield significantly slowed the decline of C-peptide levels in children and adolescents with newly diagnosed type 1 diabetes. Further data showed that study participants on Tzield required numerically fewer insulin units and had numerically higher time in range compared to those on placebo.
read more →